

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Edris Badreddin</u>  (Last) (First) (Middle) C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD.  (Street) STAMFORD CT 06902  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SpringWorks Therapeutics, Inc. [ SWTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/03/2024		s <sup>(1)</sup>		11,772	D	\$39.4015 <sup>(2)</sup>	257,828	D	
Common Stock	06/03/2024		s <sup>(1)</sup>		4,192	D	\$40.6219 <sup>(3)</sup>	253,636	D	
Common Stock	06/03/2024		s <sup>(1)</sup>		3,651	D	\$41.3767 <sup>(4)</sup>	249,985	D	
Common Stock	06/03/2024		s <sup>(1)</sup>		385	D	\$42.0366 <sup>(5)</sup>	249,600	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.98 to \$39.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$39.98 to \$40.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.98 to \$41.955. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.99 to \$42.065. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

/s/ Francis I. Perier, Jr. as Attorney-in Fact

06/05/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.